PKC-delta and -eta, MEKK-1, MEK-6, MEK-3, and p38-delta are essential mediators of the response of normal human epidermal keratinocytes to differentiating agents.
Previous studies suggest that the novel protein kinase C (PKC) isoforms initiate a mitogen-activated protein kinase (MAPK) signaling cascade that regulates keratinocyte differentiation. However, assigning these functions has relied on treatment with pharmacologic inhibitors and/or manipulating kinase function using overexpression of wild-type or dominant-negative kinases. As these methods are not highly specific, an obligatory regulatory role for individual kinases has not been assigned. In this study, we use small interfering RNA knockdown to study the role of individual PKC isoforms as regulators of keratinocyte differentiation induced by the potent differentiating stimulus, 12-O-tetradecanoylphorbol-13-acetate (TPA). PKC-delta knockdown reduces TPA-activated involucrin promoter activity, nuclear activator protein-1 factor accumulation and binding to DNA, and cell morphology change. Knockdown of PKC downstream targets, including MEKK-1, MEK-6, MEK-3, or p38-delta, indicates that these kinases are required for these responses. Additional studies indicate that knockdown of PKC-eta inhibits TPA-dependent involucrin promoter activation. In contrast, knockdown of PKC-alpha (a classical PKC isoform) or PKC-epsilon (a novel isoform) does not inhibit these TPA-dependent responses. Further studies indicate that PKC-delta is required for calcium and green tea polyphenol-dependent regulation of end responses. These findings are informative as they suggest an essential role for selected PKC and MAPK cascade enzymes in mediating a range of end responses to a range of differentiation stimuli in keratinocytes.
Adhikary
Gautam
G
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Chew
Yap Ching
YC
Reece
E Albert
EA
Eckert
Richard L
RL
D016588:Anticarcinogenic Agents / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002273:Carcinogens / Q000494:pharmacology; D002392:Catechin / Q000031:analogs & derivatives / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D000078404:Epidermal Cells; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000201:enzymology*; D048371:MAP Kinase Kinase 3 / Q000235:genetics / Q000378:metabolism*; D048669:MAP Kinase Kinase 6 / Q000235:genetics / Q000378:metabolism*; D048728:MAP Kinase Kinase Kinase 1 / Q000235:genetics / Q000378:metabolism*; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000502:physiology; D048292:Mitogen-Activated Protein Kinase 13 / Q000235:genetics / Q000378:metabolism*; D011401:Promoter Regions, Genetic / Q000502:physiology; D011493:Protein Kinase C / Q000235:genetics / Q000378:metabolism; D051745:Protein Kinase C-delta / Q000235:genetics / Q000378:metabolism*; D011498:Protein Precursors / Q000235:genetics; D034741:RNA, Small Interfering; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D018808:Transcription Factor AP-1 / Q000378:metabolism
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D011498:Protein Precursors; D034741:RNA, Small Interfering; D018808:Transcription Factor AP-1; C032253:involucrin; D002392:Catechin; C045651:epigallocatechin gallate; D048292:Mitogen-Activated Protein Kinase 13; C081975:protein kinase C eta; D011493:Protein Kinase C; D051745:Protein Kinase C-delta; D048728:MAP Kinase Kinase Kinase 1; C482576:MAP3K1 protein, human; D048371:MAP Kinase Kinase 3; D048669:MAP Kinase Kinase 6; C482530:MAP2K3 protein, human; C482566:MAP2K6 protein, human; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium
J Biol Chem. 1995 May 26;270(21):12614-22
7759510
J Biol Chem. 2006 Oct 6;281(40):29703-10
16901898
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):296-304
16202672
Mol Carcinog. 2006 Jun;45(6):381-8
16683253
Nature. 2001 Mar 1;410(6824):37-40
11242034
Chem Rev. 2001 Aug;101(8):2449-76
11749383
J Biol Chem. 2002 Jan 18;277(3):1828-36
11698415
J Invest Dermatol. 1992 Nov;99(5):565-71
1431218
J Invest Dermatol. 1994 Apr;102(4):409-14
7908680
J Invest Dermatol. 2002 Nov;119(5):1109-13
12445200
Cancer Res. 2001 Jun 1;61(11):4591-8
11389095
Curr Opin Cell Biol. 1997 Apr;9(2):161-7
9069266
J Cell Physiol. 1995 Apr;163(1):105-14
7896886
Skin Pharmacol Appl Skin Physiol. 1998;11(4-5):214-26
9885405
Exp Dermatol. 2000 Jun;9(3):192-9
10839717
Oncogene. 1995 Dec 21;11(12):2681-7
8545126
J Invest Dermatol. 2004 Jul;123(1):13-22
15191537
J Invest Dermatol. 2003 May;120(5):823-8
12713588
J Biol Chem. 2004 Jun 4;279(23):24007-14
15044435
J Biol Chem. 1990 Dec 25;265(36):22434-40
2266135
Arch Dermatol Res. 2007 May;299(2):71-83
17256148
Oncogene. 2006 Jan 19;25(3):378-86
16158048
Oncogene. 2002 May 16;21(22):3620-30
12032864
Mol Nutr Food Res. 2006 Feb;50(2):123-9
16404707
J Invest Dermatol. 2009 Oct;129(10):2365-75
19340015
J Invest Dermatol. 2008 Apr;128(4):833-45
17943181
J Biol Chem. 2001 Jul 20;276(29):27214-20
11454875
Proc Natl Acad Sci U S A. 1989 May;86(9):3099-103
2470089
Carcinogenesis. 2005 Jun;26(6):1100-8
15718254
J Investig Dermatol Symp Proc. 1999 Sep;4(2):137-44
10536988
J Invest Dermatol. 2007 Apr;127(4):775-81
17195016
Biochem Biophys Res Commun. 1992 Apr 15;184(1):283-91
1373611
J Biol Chem. 1998 Sep 18;273(38):24387-95
9733728
FEBS Lett. 1994 Jun 20;347(1):85-9
7516899
J Invest Dermatol. 1993 Oct;101(4):553-9
8409523
J Investig Dermatol Symp Proc. 2002 Dec;7(1):36-40
12518790
Mol Carcinog. 1992;5(4):286-92
1379814
J Biol Chem. 2002 Aug 30;277(35):31753-60
12080077
Cell Death Differ. 2005 Mar;12(3):224-32
15618968
Diabetes. 2001 Feb;50(2):255-64
11272134
Cancer Res. 2005 Aug 15;65(16):7356-62
16103087
J Biol Chem. 1996 Jun 21;271(25):14727-33
8663077
Mol Cell Endocrinol. 2001 May 25;177(1-2):161-71
11377831
J Biol Chem. 2001 Mar 16;276(11):8059-63
11244091
J Biol Chem. 2002 May 10;277(19):17032-40
11864971
J Biol Chem. 2003 Sep 5;278(36):34277-85
12810719
Nat Rev Mol Cell Biol. 2010 Feb;11(2):103-12
20094051
Proc Natl Acad Sci U S A. 1984 Jan;81(2):607-10
6320198
Biochim Biophys Acta. 1985 Sep 9;822(2):219-42
3161542
J Invest Dermatol. 2009 Aug;129(8):2011-21
19194472
Oncogene. 2007 May 14;26(22):3100-12
17496909
Biochem Cell Biol. 2004 Dec;82(6):658-63
15674433
Biochem J. 1998 Jun 1;332 ( Pt 2):281-92
9601053
Carcinogenesis. 2000 May;21(5):887-91
10783308
Cell Adhes Commun. 1998 Jan;5(1):1-12
9638337
Mol Cell Biol. 2004 Sep;24(18):8167-83
15340077
Exp Cell Res. 1993 Jun;206(2):235-43
8500546
Science. 1992 Oct 23;258(5082):607-14
1411571
Prog Biophys Mol Biol. 1999;71(3-4):479-500
10354710
Exp Cell Res. 1989 Nov;185(1):176-90
2509226
J Biol Chem. 2000 Jan 21;275(3):1601-7
10636851
Trends Biochem Sci. 2000 Jan;25(1):7-9
10637602